Abstract
Background
The use of radiotherapy is frequently required in the treatment of locally advanced esophageal squamous cell carcinoma. However, the margins of the tumor are often difficult to ascertain on computed tomography. Thus, EUS-guided fiducial marker insertion can aid the localization of the margins of the tumor. However, the optimal technique of the procedure is still uncertain.
Methods
This was a retrospective study of all patients that received EUS-guided fiducial marker insertion between March 2015 and December 2018. All patients suffering from esophageal squamous cell carcinoma scheduled for radiotherapy underwent the procedure within one week of the scheduled appointment. Gold fiducial markers were inserted under EUS guidance either intratumorally or within the submucosa just proximal and distal to the tumor. Outcome parameters included tumor characteristics, early and late migration rates, and tumor response rates.
Results
During the study period, 40 patients were recruited. 10 fiducial markers were placed intratumorally and 30 markers were placed submucosally. When comparing fiducials that were placed in the submucosa versus intratumorally, significantly more fiducials had early (40% vs 0%, RR = 0.6, 95% CI 0.36, 1.00) and late migration (60% vs 0%, RR = 0.33, 95% CI 0.13, 0.84) in the intratumoral group. The submucosal group had significantly more patients intended for curative intent (96.7% vs 70%, RR = 0.34, 95%CI 0.003, 0.361) and more patients with partial and complete response. There was no difference between the gross tumor volume, the clinical target volume, and the total radiation dose.
Conclusion
In esophageal carcinomas planned for radiotherapy, fiducial markers placed in the submucosa may lead to less migration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shapiro J, van Lanschot JJB, Hulshof M et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098
Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234
Shridhar R, Almhanna K, Hoffe SE et al (2013) Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis. Cancer 119:1636–1642
Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T (2011) Definitive chemoradiation for oesophageal cancer–a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 23:182–188
Machiels M, Jin P, van Hooft JE et al (2019) Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers. Acta Oncol 58:943–950
Fernandez DC, Hoffe SE, Barthel JS et al (2013) Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol 3:32–39
DaVee T, Ajani JA, Lee JH (2017) Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol 23:751–762
Cotton PB, Eisen GM, Aabakken L et al (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 71:446–454
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–47
Lightdale CJ, Kulkarni KG (2005) Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 23:4483–4489
Chavalitdhamrong D, DiMaio CJ, Siersema PD, Wagh MS (2015) Technical advances in endoscopic ultrasound-guided fiducial placement for the treatment of pancreatic cancer. Endosc Int Open 3:E373–E377
Machiels M, van Hooft J, Jin P et al (2015) Endoscopy/EUS-guided fiducial marker placement in patients with esophageal cancer: a comparative analysis of 3 types of markers. Gastrointest Endosc 82:641–649
Funding
This study was not supported by any research grant.
Author information
Authors and Affiliations
Contributions
SMC—Performing the procedures, data collection, data analysis, manuscript writeup. TT—Performing radiotherapy planning and RT for patients, data collection, manuscript writeup. HCY—Performing the procedures and manuscript review. DLC—Performing the procedures, data collection, manuscript review. DCML—Supervising RT planning, manuscript review. PWYC—Overall supervisor, manuscript review. EKWN—Overall supervisor, manuscript review. AYBT—Performing procedures, manuscript review, overall supervisor.
Corresponding author
Ethics declarations
Disclosures
Prof. Anthony Y. B. Teoh is a consultant for Boston Scientific, Cook, Taewoong and Microtech Medical Corporations. Drs. S Chan, T Tse, H Yip, D Chan, D Lam, P Chiu, E Ng have no conflicts of interest or financial ties to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 Video of EUS-guided fiducial marker with linear echoendoscope in a non-obstructive esophageal carcinoma with the submucosal technique (MP4 30994 kb)
Rights and permissions
About this article
Cite this article
Chan, S.M., Tse, T., Yip, H.C. et al. EUS-guided fiducial marker insertion for radiotherapy in advanced esophageal carcinoma: submucosal insertion may lead to less migration when compared to intratumoral insertion. Surg Endosc 36, 1666–1674 (2022). https://doi.org/10.1007/s00464-021-08711-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-021-08711-8